Creo Medical Group (LSE:CREO) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:CREO Creo Medical Group PLC LSE:CREO
41 GF Score
Price £0.13
GF Value £0.16
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

LSE:CREO
41GF Score
Creo Medical Group PLC LSE:CREO
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Creo Medical Group (LSE:CREO) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of £0.13 is trading 21.9% below its estimated GF Value™ of £0.16. GuruFocus considers Creo Medical Group to be Modestly Undervalued.

Key valuation signals for LSE:CREO:

  • Cash Payments:
  • GF Value™: £0.16 vs. price of £0.13 (21.9% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the LSE:CREO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Creo Medical Group Business Description

Other Exchanges CMEOF:USA
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
41GF Score

Get the complete analysis for LSE:CREO

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.13
Price
£0.16
GF Value